Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DNMT1
REST API REST API
Homo sapiens
DNMT1 is differentially expressed in 302 experiments: 113 organism parts: bone marrow, cerebellum, ... (111 more);, 207 disease states: normal, Burkitt's lymphoma, ... (205 more);, 99 cell types 367 cell lines 39 compound treatments and 76 other conditions.
Synonyms DNMT, CXXC9, MCMT
Orthologs Dnmt1 (Mus musculus)   DNMT1_BOVIN (Bos taurus)   dnmt1 (Danio rerio)   F6XUV4_CIOIN (Ciona intestinalis)   DNMT1_RAT (Rattus norvegicus)   dnmt1 (Xenopus laevis)   DNMT1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA methylation, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, positive regulation of histone H3-K4 methylation, regulation of cell proliferation, positive regulation of gene expression, replication fork, metal ion binding, DNA (cytosine-5-)-methyltransferase activity, heterochromatin, centromeric heterochromatin, transcription factor binding, methyltransferase activity, nucleus, regulation of gene expression, gene silencing, transferase activity, chromatin modification, negative regulation of transcription from RNA polymerase II promoter, zinc ion binding, negative regulation of histone H3-K9 methylation, maintenance of DNA methylation, DNA-methyltransferase activity, cellular response to amino acid stimulus, C-5 methylation of cytosine
InterPro Term Znf_CXXC, BAH_dom, DMAP1-bd, C5_MeTfrase, DNA_C5-MeTrfase_1_euk, Cytosine_MeTrfase1_RFD
UniProt Accession P26358, B3KVA0, Q59FP7, F5GX68
Gene-Disease Assocation NEUROPATHY, HEREDITARY SENSORY, TYPE IE; HSN1E
Search EB-eye ENSG00000130816
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-6573, E-MEXP-433, E-GEOD-7540, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (37 experiments)

Factor Value U/D Experiments
A549
2
E-GEOD-3202, E-GEOD-6013
HL-60
2
E-MTAB-37, E-GEOD-96
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
MCF-7
1
2
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
361 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, E-GEOD-21750, ... (50 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3204, E-GEOD-3920, E-GEOD-26672
CD8+ T cell
2
E-AFMX-5, E-GEOD-6740
2
E-TABM-130, E-TABM-145
astrocyte
1
E-GEOD-4483
B lymphocyte
1
E-GEOD-6691
CD133-/alpha2 integrin low prostate epithelial cell
1
E-MEXP-993
93 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MTAB-62, E-GEOD-5370, ... (62 experiments)

Factor Value U/D Experiments
myeloma
3
E-MTAB-37, E-MTAB-62, E-MTAB-317
dermatomyositis
3
E-MTAB-62, E-GEOD-5370, E-GEOD-1551
glioblastoma
3
E-GEOD-4290, E-GEOD-6014, E-MTAB-37
chronic lymphocytic leukemia
2
E-MTAB-37, E-GEOD-6691
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
colon carcinoma
2
E-MTAB-62, E-MTAB-37
201 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-3720, ... (24 experiments)

Factor Value U/D Experiments
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
lipopolysaccharide
2
E-MEXP-1958, E-GEOD-3720
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
unknown
1
E-GEOD-7307
glucose
1
E-MEXP-941
glutamine
1
E-MEXP-941
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (8 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21887, E-GEOD-3013 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-17476, E-GEOD-22593, E-TABM-321, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-6432, E-GEOD-5681, E-TABM-127, E-GEOD-20504, E-MEXP-1446, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-1926, E-MEXP-2069, ... (31 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-980

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-2487, ... (7 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

tissue (organ)
studied in E-GEOD-22601

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.325 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM